Either genetic KO or pharmacological inhibition results in significantly decreased tumor growth in vivo, an effect that is T cell dependent and can essentially flip the immune phenotype of an immunosuppressive, non–T cell–inflamedline into a more CD8+-enriched microenvironment. This evidence concerns the gene CD8A and neoplasm.